A b s t r a c t
The diagnosis of chronic myeloproliferative disorders historically has relied on combining the clinical history, morphologic features of the peripheral blood and/or bone marrow samples, and cytogenetic information. While the t(9;22) defines all cases of chronic myelogenous leukemia (CML) under the new World Health Organization classification system, 1 clonal cytogenetic abnormalities reportedly are identified in only 30% to 40% of the myeloproliferative disorders that are not CML. 2 Other techniques that can aid in the diagnosis of the non-CML myeloproliferative disorders (NCMPDs), such as the endogenous erythroid colony formation assay in the workup of polycythemia vera, 3 are highly specialized assays that cannot be performed by most hematopathology laboratories. Therefore, while the diagnosis of CML is straightforward using existing techniques, there is a pressing need for new sensitive and objective assays to aid in the diagnosis of the NCMPDs.
Multiparametric flow cytometry represents a highly reproducible and objective way of assessing the expression of multiple antigens on a single cell. By comparing patterns of antigen expression on a given cell population with the patterns identified on normal cells of that type, one potentially can identify abnormalities that, if sufficiently great, may substitute for clonality studies in identifying malignancy. A small number of studies during the past decade have reported abnormalities of one or a few myeloid antigens in CML, including decreased CD16, [4] [5] [6] decreased CD32, 5 decreased L-selectin expression on CD34+ cells, 7 aberrant expression of CD56 on blasts and myeloid cells, 8, 9 and aberrant expression of lymphoid antigens such as CD2, CD5, and CD7 on the blasts in CML blast crisis. 10 Reported flow cytometric abnormalities among the NCMPDs have included the B IgG2a-FITC/IgG1-PE/CD45-ECD/IgG2a-PE-Cy5 HLA-DR-FITC/CD33-PE/CD45-ECD/CD14-PE-Cy5 CD15-FITC/CD11b-PE/CD45-ECD/CD34-PE-Cy5 HLA-DR-FITC/CD13-PE/CD45-ECD/CD16-PE-Cy5 CD38-FITC/CD117-PE/CD45-ECD/CD34-PE-Cy5 CD5-FITC/CD56-PE/CD19-ECD/CD45-PE-Cy5 CD2-FITC/CD7-PE/CD45-ECD/CD34-PE-Cy5
Panel A was used from approximately June 1998 through October 2000, and panel B was used from November 2000 through the end of the study period in December 2001. Anti-CD45 antibodies were included in each tube for gating purposes, 18 while the combinations of the other 3 antibodies were designed empirically to maximize our ability to identify antigenic abnormalities among the myeloid blasts, maturing myeloid cells, and maturing monocytes. The specific clones used were obtained from BC, Becton Dickinson (BD, San Jose, CA) or DAKO (Carpinteria, CA) as follows: CD45-ECD (BC, J.33), IgG2a-FITC isotype control (BD), IgG1-PE/ isotype control (BD), IgG2a-PE-Cy5 isotype control (BC), HLA-DR-FITC (BD, L243), CD33-PE (BD, P67.6), CD14-PE-Cy5 (BC, RM052), CD15-FITC (BD, LeuM1), CD15-PE-Cy5 (BC, 80H5), CD11b-PE (BD, Leu15), CD34-FITC (BD, HPCA2), CD34-PE-Cy5 (BC, 581), CD13-PE (BD, LeuM7), CD16-PECy5 (BC, 3G8), CD38-FITC (BC, T16), CD117-PE (DAKO, 104D2), CD117-PE-Cy5 (BC, 95C3), CD5-FITC (BD, Leu1), CD5-PE-Cy5 (BC, BL1a), CD56-PE (BD, NCAM16.2), CD19-PE (BD, SJ25C1), CD19-ECD (BC, HD237), CD2-FITC (BC, T11), CD7-FITC (BD, Leu9), CD7-PE (BC, 3A1), and CD10-FITC (DAKO, SS2/36). In each case the amount of antibody used was based on the manufacturer's suggestion or on titration experiments to optimize the signal/noise ratio.
Particularly useful combinations of antibodies were those that identified antigens expressed over a wide range of intensities in the population of interest. For example, the coordinate variation of HLA-DR and CD33 as myeloid blasts mature to neutrophils and monocytes made the combination of anti-HLA-DR and anti-CD33 antibodies particularly useful following: (1) increased expression of bcl-X L in polycythemia vera 11 ; (2) decreased platelet glycoprotein (GP) Ia/IIa, 12 decreased GPIb and GPIIb/IIIa, 13 and elevated platelet P-selectin, thrombospondin, GPIV, and c-Mpl 14, 15 in essential thrombocytosis; and (3) aberrant coexpression of CD14 and CD66 on the myeloid cells in a subset of myeloproliferative disorders. 16 These studies have been limited in that they generally investigated small numbers of NCMPD cases, relatively few antigens, or both. A thorough immunophenotypic evaluation of the blasts and maturing myeloid and monocytic cells in the NCMPDs has yet to be described.
In the University of Washington Hematopathology Laboratory (Seattle), we have been using 4-color flow cytometry since mid-1998 to evaluate myeloid maturation in cases clinically suspected to represent myelodysplastic or myeloproliferative disorders. We have accumulated a database of more than 500 such cases, which has permitted us to identify reproducible patterns of antigen expression in normal myelopoiesis 17 ❚Image 1❚ and in reactive settings such as bone marrow regeneration. 17 The present study evaluates the usefulness of 4-color flow cytometry vis-à-vis conventional cytogenetics in the workup of the NCMPDs and demonstrates that in experienced laboratories, 4-color flow cytometry represents a useful method to help distinguish benign from neoplastic bone marrow in this workup.
Materials and Methods
All patients whose bone marrow samples were evaluated in our laboratory by 4-color flow cytometry between June 1998 and December 2001, as part of the workup to rule out a myeloproliferative disorder, were identified retrospectively. Patients who did not have concurrent cytogenetic evaluation of the same marrow specimen (in the University of Washington Cytogenetics Laboratory) or who had evidence of the t(9;22) were excluded from the analysis, leaving a total of 66 patients.
For all specimens, 4-color flow cytometry was performed on Coulter XL instruments (Beckman Coulter [BC], Hialeah, FL) using commercially available reagents. In the processing of all specimens, erythroid cells were bulklysed with buffered ammonium chloride, and the remaining cells were washed once with phosphate-buffered saline-bovine serum albumin (PBS-BSA)-azide, pH 7.4, and resuspended to the desired cell concentration in PBS-BSA or RPMI. Next, 100 µL of the cell suspension (5 × 10 5 to 1 × 10 6 cells) was incubated with appropriate amounts of titered antibodies for 15 minutes at room temperature in the dark, washed once with PBS-BSA-azide, and resuspended in 1% paraformaldehyde. In most cases, 100,000 to 150,000 cells were analyzed from each tube of cells and antibodies, while Once the 66 cases were identified, archival 4-color flow cytometry data from these cases, which are saved routinely in uncompensated "listmode" form on compact discs, were compensated and reanalyzed by 1 observer (S.J.K.) on a Macintosh G3 or G4 computer (Apple Computer, Cupertino, CA) using software developed in our laboratory (by B.L.W.). In all cases, the individual bone marrow cell populationsmyeloid blasts, maturing myeloid cells, maturing monocytes, B lymphoblasts, and mature lymphocytes-were identified by CD45/side scatter gating. 17 In addition, except in cases in which a CD34-(abnormal) blast population was identified, the myeloid blast gate usually was refined by largely limiting this gate to the CD34+ cells.
The patterns of antigen expression on the myeloid blasts, maturing myeloid cells, and monocytes in the 66 study cases were compared with the patterns typically seen in normal myeloid populations, as described in the "Results" section. All flow cytometric data were evaluated by 2 observers (S.J.K. and B.L.W.) without knowledge of the concurrent cytogenetic findings. The cytogenetic data, based on conventional G-banding, was obtained from the University of Washington Cytogenetics Laboratory. In most cases, the karyotypic analysis was based on 20 metaphases.
Results

Normal Patterns of Myeloid Antigen Expression With Maturation
Flow cytometric evaluation of a series of 11 negative bone marrow aspirates obtained at the time of initial staging for nonHodgkin lymphoma was used to define the range of normal myeloid antigen expression. A twelfth negative bone marrow aspirate, from a patient with iron deficiency anemia, was chosen as the "gold standard" for normal maturation (Image 1) and compared with the specimens from each of the 66 patients in the study. Note that the patterns of myeloid antigen expression in this twelfth marrow aspirate were similar to those in the other 11 control marrow aspirates, and the patterns in all 12 were very similar to those observed in all presumed-normal marrow aspirates that we have evaluated during the 5 years we have been doing this assay. Therefore, this 12-marrow aspirate control group is an appropriate normal control for this study.
Image 1 illustrates normal patterns of myeloid and monocytic antigen expression in this gold standard bone marrow aspirate. Among the myeloid blasts (Image 1A), the continuous black lines indicate the progression of maturation from the relatively immature myeloid blasts (CD34+, CD38-low/negative) through more mature myeloid blasts (CD34+, CD38+). Note that the dashed line in several of the dot plots demonstrates the characteristic loss of the myeloid-associated antigens CD33 and CD13 as erythroid differentiation occurs. In the dot plots demonstrating the expression of HLA-DR vs CD33 and vs CD13, an open circle denotes the putative blast precursor population from which the erythroblasts and later myeloblasts develop. Among the maturing granulocytes (Image 1B), the continuous black lines indicate the progression of maturation from late blast forms (CD15-and CD11b-), to promyelocytes (CD33+, CD15+, CD13+, CD11b-low/negative, HLA-DR-, and CD16-), and eventually to neutrophils (with coexpression of bright CD15, CD11b, CD13, and CD16). Among the maturing monocytes (Image 1C), the continuous black lines indicate the progression of maturation from late blast forms (CD14-, CD15-, and CD11b-), to immature monocytes (acquiring expression of CD15 and CD11b), to mature forms (with coexpression of bright CD14, CD11b, and CD13, and variable CD15). In both the granulocytic and monocytic series, the progression demonstrated in Image 1 occurs in parallel with an increase in CD45 expression. Our findings in normal myelopoiesis, which are presented in detail elsewhere, 17 are similar to those previously described by Loken and Wells, 19 Terstappen and Loken, 20 and Terstappen et al 21 using 3-color flow cytometry.
Definition of the Flow-Normal, Flow-Indeterminate, and Flow-Abnormal Groups
Cases were classified as flow-normal, flow-indeterminate, and flow-abnormal, depending on the number and severity of the antigenic alterations identified by flow cytometry. Three major types of antigenic abnormalities were identified: (1) deviations in myeloid antigen intensity, defined as an increase or decrease of at least one third of a decade on a log scale compared with normal, among at least 10% of the cells in the population of interest; (2) dyssynchronous expression of 2 myeloid antigens, which typically was seen among most of the cells in a population of interest; and (3) aberrant expression of nonmyeloid antigens, also defined as expression of the abnormal antigen by at least 10% of the cells in the population of interest.
In practice, the identification of any of these 3 types of abnormalities in any individual antigen eliminated a case from the "normal" category. However, the decision to classify a case as flow-indeterminate or flow-abnormal depended on a global view of the overall number and severity of the antigenic abnormalities by the 2 observers (S.J.K. and B.L.W.). Certain antigenic alterations, such as convincing expression of the nonmyeloid antigens CD5, CD7, or CD56 on 10% or more of the myeloid blasts, were considered sufficient to put a case into the abnormal category. Such aberrant nonmyeloid antigen expression was identified on the blasts in 9 of 30 flow-abnormal cases. For the remaining 21 flow-abnormal cases, the decision to classify as abnormal largely came down to the number of antigenic abnormalities and to the severity of the individual abnormalities.
For example, cases showing mild alterations of 1 or 2 antigens, such as CD33 expression increased or decreased by one half of a log relative to the normal control marrow, generally were classified as indeterminate, eg, case 23 in ❚Table 1❚, since we have seen a similar level of CD33 alteration in reactive settings such as marrow regeneration after chemotherapy. In rare flow-abnormal cases, such as case 14 in ❚Table 2❚, the virtual absence of CD33 expression on the myeloid blasts and maturing granulocytes and monocytes was thought to justify classification as abnormal, despite the presence of relatively normal levels of expression of the other myeloid antigens. However, among the flow-abnormal cases, the identification of multiple antigenic abnormalities was much more common than single antigenic abnormalities. Thus, the mean number of abnormal antigens among the 21 flow-abnormal cases lacking CD5, CD7, or CD56 on the blasts was 4.6, while the mean number of abnormal antigens among the 15 flow-indeterminate cases was approximately 1.8. Note that the mean abnormal antigen value of 1.2 for the normal and indeterminate cases in ❚Table 3❚ represents the mean number of abnormal antigens when the flow-normal and flow-indeterminate cases were pooled. cases, while the other 36 were flow-normal (21 cases) or flow-indeterminate (15 cases). The cases included in each of these 2 groups are described in Tables 1 and 2 . Note that while the male/female ratio was similar in the normal and indeterminate groups and the abnormal group (0.80 and 0.88, respectively), the mean age of 67.5 years in the abnormal group was significantly greater than the mean age of 55.0 years in the normal and indeterminate group (P < .001, Student t test). Strikingly, clonal cytogenetic abnormalities were found in 11 (37%) of the 30 flow-abnormal cases, compared with 0 (0%) of 36 flow-normal and flow-indeterminate cases (P < .001 for the difference in percentages). In terms of specific cytogenetic findings, 3 of 11 cytogenetically abnormal cases demonstrated chromosome 21 abnormalities (2 with trisomy 21), 3 cases demonstrated chromosome 1 abnormalities, 2 cases demonstrated 20q deletions, and the remaining 3 cytogenetically abnormal cases involved unique chromosomes (Table 2) . At present, we have been unable to obtain more complete clinical and morphologic information on all cases, so a detailed correlation of the immunophenotypes with specific categories of NCMPD has not been possible. However, based on the information available to us, it seemed that the flow-abnormal cases included cases with the features of polycythemia vera, essential thrombocytosis, chronic idiopathic myelofibrosis, chronic eosinophilic leukemia, and myeloproliferative disorder, not otherwise specified. ❚Image 2❚, ❚Image 3❚, ❚Image 4❚, ❚Image 5❚, and ❚Image 4❚ Four-color flow cytometric analysis of a case with the features of chronic idiopathic myelofibrosis. The myeloid cell populations are gated and colored as in Images 1 and 2. Note the virtual absence of CD13 expression on the myeloid blasts, maturing granulocytes ("Myeloid" dot plot), and maturing monocytes. In addition, there is decreased CD33, HLA-DR, and CD34 on the myeloid blasts; decreased side scatter (SS) on the maturing granulocytes (which typically reflects cytoplasmic hypogranularity); and abnormally bright CD16 on the monocytes. ECD, PE-Texas red; FITC, fluorescein isothiocyanate; PC5, PECy5; PE, phycoerythrin. 
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❚Image 5❚ Four-color flow cytometric analysis of a case with the features of chronic eosinophilic leukemia/hypereosinophilic syndrome. The myeloid cell populations are gated and colored as in Images 1 through 3, highlighting the markedly expanded eosinophils (yellow) and moderately expanded basophils and myeloid blasts. Note the decreased CD33 and CD38 and abnormally homogeneous HLA-DR, CD13, and CD34 on the myeloid blasts. In addition, note the mildly decreased CD33 on the neutrophils and the aberrant expression of low CD117 on the basophils (normally CD117-). ECD, PE-Texas red; FITC, fluorescein isothiocyanate; PC5, PE-Cy5; PE, phycoerythrin; SS, side scatter.
❚Image 6❚, respectively, demonstrate the flow cytometric data from abnormal cases with these 5 probable diagnoses.
Specific Immunophenotypic Abnormalities
As Table 3 demonstrates, both the blasts and maturing granulocytes were immunophenotypically abnormal in most flow-abnormal cases, while immunophenotypically abnormal monocytes were identified in just more than half of the cases. As expected, the percentage of immunophenotypically abnormal cell populations of all types was greater in the flow-abnormal group than in the flow-normal-flow-indeterminate group.
Regarding specific antigens, ❚Table 4❚ demonstrates that abnormalities of HLA-DR, CD13, and CD33 each were seen in more than 60% of the flow-abnormal cases, while the other antigens evaluated showed abnormalities in 40% or fewer of the flow-abnormal cases. Specific antigenic abnormalities seen in the flow-indeterminate group most commonly were alterations of CD13 and CD33 expression. However, for all of the antigens except CD14, the frequency of abnormalities was much lower among the flow-indeterminate group than among the flow-abnormal group. Since we invariably consider substantial expression of the nonmyeloid antigens CD5, CD7, or CD56 by blasts to be an abnormal feature, by definition none of the flow-normal-flow-indeterminate cases demonstrated these abnormalities on the blasts; the 3 flow-indeterminate cases demonstrating CD56 expression did so on the maturing myeloid or monocytic cells only. Finally, because we have been able to recognize normal basophil populations by flow cytometry for several years, with a CD11b+/CD13+/CD33+/HLA-DR-/CD15-/CD117-immunophenotype, 22, 23 we have been able to show that the flow-abnormal cases have a considerably higher rate of abnormal basophils than the flow-normal-flow-indeterminate populations. Image 3 demonstrates a normal basophil pattern of CD33 vs HLA-DR, and Images 5 and 6 show abnormal basophil populations.
Correlation Between Immunophenotypic and Cytogenetic Abnormalities
Among the 30 immunophenotypically abnormal cases there was a tendency for a greater number of cytogenetic abnormalities to be associated with more extensive immunophenotypic abnormalities, although this tendency did not reach statistical significance (P = .64). 
Discussion
We have demonstrated that 4-color flow cytometry is capable of identifying substantial antigenic abnormalities in essentially all cytogenetically abnormal bone marrow aspirates undergoing workup for an NCMPD. By extension, the results suggest that antigenic abnormalities will be identifiable in many of the NCMPDs that are cytogenetically normal. Because the NCMPDs historically have lacked highly sensitive and objective diagnostic criteria, the present findings indicate that, in experienced laboratories, flow cytometry represents a useful method to add to the clinical history and marrow morphologic features to help distinguish benign from neoplastic marrow.
Based on incomplete morphologic data on the bone marrow aspirates in the flow-abnormal cases, there was no obvious correlation between specific antigenic abnormalities and the specific type of NCMPD, although marrow eosinophils-identified by expression of relatively bright CD11b, CD13, CD15, and CD45, without CD16-were expanded markedly in the patients with putative chronic eosinophilic leukemia (Image 5). However, the discriminatory ability of flow cytometry for specific types of NCMPD potentially could be improved by examining cell types other than the myeloblasts and maturing granulocytes and monocytes. For example, flow cytometric examination of erythroid precursors, which has been shown to be useful in the evaluation of myelodysplastic syndromes, 24 may prove to be an additional aid in the diagnosis of polycythemia vera; increased expression of bcl-X L already has been identified as an antigenic abnormality in polycythemia vera. 11 Similarly, the diagnosis of both essential thrombocytosis and chronic idiopathic myelofibrosis, in which abnormal megakaryocytes are prominent, potentially could be improved by evaluating platelet antigens such as P-selectin, thrombospondin, and c-Mpl. 14, 15 In our series, the antigens that were altered most commonly in the NCMPDs included CD13, CD33, and HLA-DR, followed by CD16. Based on these findings, it seems that the 2 assay tubes in which we combine (1) HLA-DR (FITC), CD33 (PE), CD45 (ECD), and CD14 (PE-Cy5) and (2) HLA-DR (FITC), CD13 (PE), CD45 (ECD), and CD16 (PE-Cy5) are particularly useful for identifying abnormalities in the NCMPDs. The usefulness of examining CD13 vs CD16 in normal and abnormal granulocyte maturation has been described. 19, 24 Note that it took several years for our laboratory to optimize the combinations of antibodies used to evaluate myeloid maturation in the marrow. However, our detailed descriptions of these antibody combinations (see the "Materials and Methods" section) and the normal expression patterns of the corresponding antigens (Image 1 and Kussick and Wood 17 ) may help other flow cytometry laboratories develop a similar 4-color method in a relatively efficient manner.
In addition to helping identify a potential NCMPD, 4-color flow cytometry offers an objective method for monitoring the course of the patient's disease. We have seen cases in which the immunophenotypic abnormalities have remained remarkably stable and others in which the immunophenotypic abnormalities have progressed. For example, case 12 in the abnormal group, on which we performed flow cytometry 5 times during a 5-year period, has shown a persistently low marrow blast percentage; stable loss of CD13 expression on the blasts, granulocytes, and monocytes (Image 4); and a persistently normal karyotype. Conversely, in the year and a half between our 2 flow cytometric evaluations of case 24 in the abnormal group, the blasts acquired expression of aberrant CD7 and CD11b and, in parallel, developed a clonal cytogenetic abnormality (trisomy 13), whereas the initial marrow cytogenetic evaluation was normal.
Our data go beyond the data in most of the previous publications about the use of flow cytometry in the workup of the myeloproliferative disorders, in both the number of cases and the number of antigens evaluated. Previous studies typically have focused on one or a few myeloid antigens, including abnormal CD16 and CD56 in CML 4, 5, 8, 9 or in both CML and NCMPDs 6 ; asynchronous CD14 and CD66 in a subset of myeloproliferative disorders 16 ; elevated platelet surface expression of P-selectin, thrombospondin, and c-Mpl in essential thrombocytosis 14, 15 ; and increased expression of bcl-X L in polycythemia vera. 11 These studies generally did not use the 4-color technology that we used and generally did not have such a large series of cases. * Data are given as number (percentage).
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From a methodological perspective, our study seems most comparable to the 2001 study by Stetler-Stevenson and colleagues, 24 which made the important observation that flow cytometry can be useful for distinguishing reactive from dysplastic bone marrow samples in morphologically equivocal cases of myelodysplasia. As in our study, StetlerStevenson and colleagues 24 found that abnormal patterns of expression of CD11b vs CD16 or CD13 vs CD16 among the maturing granulocytes were particularly useful for distinguishing benign from dysplastic processes, while aberrant expression of nonmyeloid antigens and loss of CD10 among the neutrophils were less common findings. They found that loss of CD64 among the granulocytes was present in about two thirds of patients with myelodysplastic syndromes, while CD64 was not one of the antigens routinely evaluated in our panels. In addition, they attempted to evaluate maturing megakaryocytes by flow cytometry, which we have not attempted to do because of our concerns that platelet binding to the surfaces of nonmegakaryocytic cells might result in artifactual positivity for platelet-associated antigens.
In addition to the different type of myeloid stem cell abnormality being evaluated, our study differs from the study by Stetler-Stevenson et al 24 in 2 respects. First, our cases were identified solely because of a clinical suspicion of a myeloproliferative disorder, rather than being preselected following morphologic and cytogenetic characterization of the bone marrow samples. Second, we used 4-color flow cytometry rather than a 3-color approach.
Our findings do not exclude the possibility that certain cases that qualify as NCMPDs based on clinical and morphologic grounds will lack substantial flow cytometric abnormalities. In addition, in the absence of detailed clinical and morphologic information on these cases, we cannot determine the added value of flow cytometry beyond the triad of clinical history, blood and marrow morphologic findings, and conventional cytogenetics. We hope to obtain such clinical and morphologic information in the future to quantify the sensitivity and specificity of flow cytometry in the diagnosis of NCMPDs. However, at present, we can say with assurance that virtually all NCMPD cases bearing clonal cytogenetic abnormalities will be identified as abnormal by our 4-color flow cytometric method.
